Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myopic Choroidal Neovascularization

Conditions

Myopic Choroidal Neovascularization

Trial Timeline

Jun 16, 2021 → Nov 11, 2022

NCT ID

NCT04524910

About Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) is a pre-clinical stage product being developed by Bayer for Myopic Choroidal Neovascularization. The current trial status is completed. This product is registered under clinical trial identifier NCT04524910. Target conditions include Myopic Choroidal Neovascularization.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05511038	Approved	Completed	Aug 26, 2022	Apr 16, 2024	Diabetic Macular Edema
NCT04524910	Pre-clinical	Completed	Jun 16, 2021	Nov 11, 2022	Myopic Choroidal Neovascularization
NCT04641234	Pre-clinical	Completed	Dec 11, 2020	Jun 9, 2021	Neovascular Age-related Macular Degeneration
NCT02818998	Phase 3	Completed	Nov 16, 2016	Sep 24, 2019	Macular Edema
NCT02540954	Phase 3	Completed	Sep 29, 2015	Jun 4, 2020	Macular Degeneration
NCT02289924	Pre-clinical	Completed	Jan 9, 2015	Jul 8, 2019	Wet Macular Degeneration

Competing Products

1 competing product in Myopic Choroidal Neovascularization

See all competitors

Product	Company	Stage	Hype Score
Intravitreal Pegaptanib	Pfizer	Pre-clinical	22

Other Products from Bayer

TelmisartanApproved

Clotrimazole vaginal tablet + FluconazoleApproved

Levitra (Vardenafil, BAY38-9456)Approved

Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved

Rivaroxaban 20 MG + WarfarinApproved